Los puntos clave no están disponibles para este artículo en este momento.
Proteolysis-targeting chimeras (PROTACs) have emerged as potentially effective therapeutic medicines, but their high molecular weight and poor solubility directly impact their oral bioavailability. This work synthesized
He et al. (Mon,) studied this question.